Rallybio Corp. (RLYB)
16.64
+0.24
(+1.46%)
USD |
NASDAQ |
Oct 23, 16:00
16.48
-0.16
(-0.96%)
After-Hours: 20:00
Rallybio Enterprise Value : -4.542M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -4.542M |
| October 22, 2026 | -5.816M |
| October 21, 2026 | -6.771M |
| October 20, 2026 | -5.922M |
| October 19, 2026 | -6.081M |
| October 16, 2026 | -6.453M |
| October 15, 2026 | -3.826M |
| October 14, 2026 | -3.136M |
| October 13, 2026 | -4.118M |
| October 12, 2026 | -3.746M |
| October 09, 2026 | -2.526M |
| October 08, 2026 | -2.685M |
| October 07, 2026 | -3.003M |
| October 06, 2026 | -2.207M |
| October 05, 2026 | -3.162M |
| October 02, 2026 | -2.207M |
| October 01, 2026 | -3.905M |
| September 30, 2026 | -1.570M |
| September 29, 2026 | -1.464M |
| September 28, 2026 | -2.366M |
| September 25, 2026 | -4.648M |
| September 24, 2026 | -4.701M |
| September 23, 2026 | -3.375M |
| September 22, 2026 | -3.056M |
| September 21, 2026 | -3.003M |
| Date | Value |
|---|---|
| September 18, 2026 | -1.623M |
| September 17, 2026 | -1.783M |
| September 16, 2026 | -2.154M |
| September 15, 2026 | -1.464M |
| September 14, 2026 | -5.232M |
| September 11, 2026 | -3.295M |
| September 10, 2026 | -3.958M |
| September 09, 2026 | -2.791M |
| September 08, 2026 | -4.701M |
| September 04, 2026 | -3.030M |
| September 03, 2026 | -3.295M |
| September 02, 2026 | -2.950M |
| September 01, 2026 | -4.277M |
| August 31, 2026 | -3.746M |
| August 28, 2026 | -3.64M |
| August 27, 2026 | -3.905M |
| August 26, 2026 | -3.268M |
| August 25, 2026 | -3.242M |
| August 24, 2026 | -3.693M |
| August 21, 2026 | -3.534M |
| August 20, 2026 | -4.754M |
| August 19, 2026 | -2.632M |
| August 18, 2026 | -3.852M |
| August 17, 2026 | -2.632M |
| August 14, 2026 | -2.685M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 43.66M |
| Total Expenses (Quarterly) | -43.66M |
| EPS Diluted (Quarterly) | 7.531 |
| Earnings Yield | 46.95% |
| Normalized Earnings Yield | 14.90 |